Compare Crocs, Inc. (CROX) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Immunovant Inc. Common Stock — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.60B), while Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B). The key difference: Crocs, Inc. and Immunovant Inc. Common Stock are close in size by market cap, and Crocs, Inc. is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Immunovant Inc. Common Stock for 0 Days on average.
| CROX | IMVT | |
|---|---|---|
Market Cap | $5.60B | $6.25B |
Volume | 1,026,773 | 1,755,411 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $44.96 |
52-Week Low | $73.39 | $17.03 |
Typical Hold Time | 96 Days | 0 Days |
Enterprise Value | $7.12B | $5.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
